Values as of: 2019-01-16
ETF | Large Blend | NYSE Arca
Last Closing
USD 30.9467Change
+0.15 (+0.49)%Market Cap
USD 6.73MVolume
9.36KAnalyst Target
N/A
N/A
Verdict
The investment seeks to provide capital appreciation. The fund invests at least 65% of its net assets in a portfolio of equity securities of publicly traded U.S. companies. Equity securities include common stocks and common or preferred shares of real estate investment trusts. The fund may invest in small-, mid- and large-capitalization companies. It is non-diversified.
Company Website : www.alpsfunds.com
Currency: USD
Country : USA
Inception Date: 06/06/2016
Primary Benchmark: S&P 1500 TR
Primary Index: S&P 500 TR USD
Gross Expense Ratio: NA%
Management Expense Ratio: 0.52 %
N/A
N/A
| Symbol | Company Name | Allocation |
|---|---|---|
| SCPS | Scopus Biopharma Inc | 2.65 % |
| EMMA | Emmaus Life Sciences Inc | 2.14 % |
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| VTI | Vanguard Total Stock Market In.. | 0.03 % |
-1.19 (-0.47%) |
USD 1,599.41B |
| SPY | SPDR S&P 500 ETF Trust | 0.09 % |
-1.92 (-0.38%) |
USD 528.58B |
| IVV | iShares Core S&P 500 ETF | 0.04 % |
-2.15 (-0.42%) |
USD 428.78B |
| VOO | Vanguard S&P 500 ETF | 0.03 % |
-1.92 (-0.41%) |
USD 419.07B |
| VIG | Vanguard Dividend Appreciation.. | 0.06 % |
-0.36 (-0.20%) |
USD 77.60B |
| RSP | Invesco S&P 500® Equal Weight.. | 0.20 % |
-0.34 (-0.21%) |
USD 53.38B |
| ITOT | iShares Core S&P Total U.S. St.. | 0.03 % |
-0.51 (-0.46%) |
USD 51.22B |
| SCHX | Schwab U.S. Large-Cap ETF | 0.03 % |
-0.15 (-0.25%) |
USD 40.18B |
| IWB | iShares Russell 1000 ETF | 0.15 % |
-1.12 (-0.40%) |
USD 33.43B |
| VV | Vanguard Large-Cap Index Fund .. | 0.04 % |
-0.91 (-0.39%) |
USD 32.71B |
N/A
| Market Performance vs. Industry/Classification (Large Blend) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 6.64% | 90% | A- | 62% | D | ||
| Dividend Return | N/A | N/A | N/A | N/A | F | ||
| Total Return | 6.64% | 89% | A- | 62% | D | ||
| Trailing 12 Months | |||||||
| Capital Gain | -9.33% | 20% | F | 50% | F | ||
| Dividend Return | 1.16% | 19% | F | 19% | F | ||
| Total Return | -8.17% | 14% | F | 44% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | F | ||
| Total Return | N/A | N/A | N/A | N/A | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 8.92% | 66% | D+ | 76% | C+ | ||
| Dividend Return | 9.61% | 50% | F | 72% | C | ||
| Total Return | 0.69% | 25% | F | 15% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 9.95% | 26% | F | 67% | D+ | ||
| Risk Adjusted Return | 96.58% | 43% | F | 83% | B | ||
| Market Capitalization | 6.73M | 52% | F | 27% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
There is nothing we particularly like
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
